Fanconi anemia
Drug research and approvals for fanconi anemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 24 studies of fanconi anemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 24
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi AnemiaNCT07901959 · Phase 1 · Rockefeller University · starts Oct 14, 2026
- Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National…NCT07877727 · Not reported · Istituto Giannina Gaslini · starts May 29, 2025
- MRI as Noninvasive Innovative Approach in Detection and Monitoring of Malignant Oral Lesions in Fanconi Anemia PatientsNCT07649031 · Not reported · University of Minnesota · starts Jun 23, 2026
- Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage DiseaseNCT07459582 · Not reported · Connecticut Children's Medical Center · starts Sep 18, 2026
- A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer…NCT07036731 · Not applicable · The First Affiliated Hospital with Nanjing Medical University · starts Feb 1, 2025
- DFT383 in Pediatric Participants With Nephropathic CystinosisNCT06910813 · Phase 1 / Phase 2 · Novartis Pharmaceuticals · starts Jun 2, 2025
- Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)NCT06648096 · Phase 1 / Phase 2 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · starts Nov 8, 2024
- Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced MalignanciesNCT06458712 · Phase 1 · Duke Street Bio Ltd · starts Nov 21, 2024
- The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With…NCT06287541 · Not applicable · The First Affiliated Hospital with Nanjing Medical University · starts Jul 1, 2023
Phase 2 9
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- CyclophosphamideDNA inhibitor
- Fludarabine
- PlerixaforC-X-C chemokine receptor type 4 partial agonist
- BusulfanDNA inhibitor
- EltrombopagThrombopoietin receptor agonist
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- SirolimusFK506-binding protein 1A inhibitor
Phase 1 or earlier 12
- CyclosporineCyclophilin A modulator
- AlemtuzumabCAMPATH-1 antigen inhibitor
- DanazolProgesterone receptor agonist
- MethotrexateDihydrofolate reductase inhibitor
- OxandroloneAndrogen Receptor agonist
- RituximabB-lymphocyte antigen CD20 binding agent
- PrednisoneGlucocorticoid receptor agonist
- AmifostineReactive metabolite scavenging agent
- BriquilimabStem cell growth factor receptor inhibitor
- Quercetin
- Mozafancogene autotemcel
- EtanerceptTNF-alpha inhibitor
How its trials ended
93 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 23 whose ending is known, 30% met their primary endpoint, 0% missed it and 70% stopped early.
- Completed, result not reported4043%
- Ongoing2426%
- Met its primary endpoint78%
- Stopped: other or unclear66%
- Status unknown66%
- Stopped: enrollment or feasibility44%
- Stopped: sponsor or business decision33%
- Stopped: lack of efficacy22%
- Stopped: funding11%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| May 2, 2016 | Fancalen (lentiviral vector containing the Fanconi anemia-A…Treatment of Fanconi anemia type A patients. | Rocket Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA